GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Waters Corp (NYSE:WAT) » Definitions » Cash And Cash Equivalents

Waters (Waters) Cash And Cash Equivalents : $395 Mil (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Waters Cash And Cash Equivalents?

Waters's quarterly cash and cash equivalents increased from Jun. 2023 ($329.69 Mil) to Sep. 2023 ($336.41 Mil) and increased from Sep. 2023 ($336.41 Mil) to Dec. 2023 ($395.08 Mil).

Waters's annual cash and cash equivalents declined from Dec. 2021 ($501.23 Mil) to Dec. 2022 ($480.53 Mil) and declined from Dec. 2022 ($480.53 Mil) to Dec. 2023 ($395.08 Mil).


Waters Cash And Cash Equivalents Historical Data

The historical data trend for Waters's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waters Cash And Cash Equivalents Chart

Waters Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 335.72 436.70 501.23 480.53 395.08

Waters Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 480.53 486.07 329.69 336.41 395.08

Waters Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Waters  (NYSE:WAT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Waters Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Waters's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Waters (Waters) Business Description

Traded in Other Exchanges
Address
34 Maple Street, Milford, MA, USA, 01757
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.
Executives
Christopher A Kuebler director 210 CARNEGIE CENTER, PRINCETON NJ 08540
Richard H Fearon director 1239 GERBING ROAD, AMELIA ISLAND FL 32034
Edward Conard director
Daniel J. Brennan director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Mark P Vergnano director 1007 MARKET STREET, WILMINGTON DE 19898
Gary E Hendrickson director 1101 THIRD STREET SOUTH, MINNEAPOLIS MN 55415
John M Ballbach director
Linda Baddour director PRA INTERNATIONAL, 12120 SUNSET HILLS ROAD, SUITE 600, RESTON VA 20190
Michael J Berendt director
Thomas P Salice director
Wei Jiang director 34 MAPLE STREET, MILFORD MA 01757
Amol Chaubal officer: SVP and Chief Financial Office 113 HARTWELL AVE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421
Jianqing Bennett officer: SVP TA Instruments Division 34 MAPLE STREET, MILFORD MA 01757
Joann A Reed director C/O AMERICAN TOWER CORP, 116 HUNTINGTON AVENUE, BOSTON MA 02116
Belinda Hyde officer: SVP, Global Human Resources 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277

Waters (Waters) Headlines

From GuruFocus

Q1 2022 Waters Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Waters Corp Investor Day Transcript

By GuruFocus Research 01-23-2024

Waters Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Waters Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Waters Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024